The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Cancer Stat Facts: Colorectal Cancer. Available online: https://seer.cancer.gov/statfacts/html/colorect.html (accessed on 1 September 2022).
- Baron, J.A.; Beach, M.; Mandel, J.S.; Van Stolk, R.U.; Haile, R.W.; Sandler, R.S.; Rothstein, R.; Summers, R.W.; Snover, D.C.; Beck, G.J.; et al. Calcium Supplements for the Prevention of Colorectal Adenomas. N. Engl. J. Med. 1999, 340, 101–107. [Google Scholar] [CrossRef]
- Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Solomon, S.D.; Kim, K.; Tang, J.; Rosenstein, R.B.; Wittes, J.; Corle, D.; et al. Celecoxib for the Prevention of Sporadic Colorectal Adenomas. N. Engl. J. Med. 2006, 355, 873–884. [Google Scholar] [CrossRef]
- Benamouzig, R.; Deyra, J.; Martin, A.; Girard, B.; Jullian, E.; Piednoir, B.; Couturier, D.; Coste, T.; Little, J.; Chaussade, S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003, 125, 328–336. [Google Scholar] [CrossRef]
- Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, K.; Miyake, H.; Niitsu, Y. Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer. N. Engl. J. Med. 1998, 339, 1277–1284. [Google Scholar] [CrossRef]
- Hurlstone, D.P.; Karajeh, M.; Sanders, D.S.; Drew, S.K.; Cross, S.S. Rectal Aberrant Crypt Foci Identified Using High-Magnification-Chromoscopic Colonoscopy: Biomarkers for Flat and Depressed Neoplasia. Am. J. Gastroenterol. 2005, 100, 1283–1289. [Google Scholar] [CrossRef]
- Seike, K.; Koda, K.; Oda, K.; Kosugi, C.; Shimizu, K.; Nishimura, M.; Shioiri, M.; Takano, S.; Ishikura, H.; Miyazaki, M. Assessment of Rectal Aberrant Crypt Foci by Standard Chromoscopy and its Predictive Value for Colonic Advanced Neoplasms. Am. J. Gastroenterol. 2006, 101, 1362–1369. [Google Scholar] [CrossRef]
- Kowalczyk, M.; Orłowski, M.; Klepacki, Ł.; Zinkiewicz, K.; Kurpiewski, W.; Kaczerska, D.; Pesta, W.; Zieliński, E.; Siermontowski, P. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine. BMC Cancer 2020, 20, 133. [Google Scholar] [CrossRef]
- Brown, W.A.; Skinner, S.A.; Malcontenti-Wilson, C.; Vogiagis, D.; O’Brien, P.E. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001, 48, 660–666. [Google Scholar] [CrossRef] [Green Version]
- Sinicrope, F.A.; Velamala, P.R.; Song, L.M.W.K.; Viggiano, T.R.; Bruining, D.H.; Rajan, E.; Gostout, C.J.; Kraichely, R.E.; Buttar, N.S.; Schroeder, K.W.; et al. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. Cancer Prev. Res. 2019, 12, 821–830. [Google Scholar] [CrossRef] [Green Version]
- Shpitz, B. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 2003, 52, 1598–1601. [Google Scholar] [CrossRef]
- Stark, L.A.; Din, F.V.; Zwacka, R.M.; Dunlop, M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15, 1273–1275. [Google Scholar] [CrossRef] [PubMed]
- Loveridge, C.J.; MacDonald, A.D.H.; Thoms, H.C.; Dunlop, M.G.; Stark, L.A. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB. Oncogene 2008, 27, 2648–2655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jana, N.R. NSAIDs and apoptosis. Cell. Mol. Life Sci. 2008, 65, 1295–1301. [Google Scholar] [CrossRef] [PubMed]
- Luciani, M.G.; Campregher, C.; Gasche, C. Aspirin blocks proliferation in colon cells by inducing a G 1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007, 28, 2207–2217. [Google Scholar] [CrossRef] [Green Version]
- Ettarh, R.; Cullen, A.; Calamai, A. NSAIDs and Cell Proliferation in Colorectal Cancer. Pharmaceuticals 2010, 3, 2007–2021. [Google Scholar] [CrossRef] [Green Version]
- Szymański, F.M.; Filipiak, K.J.; Krasiński, Z.; Reguła, J.; Małecki, M.; Sławek, J. What aspirin dosing should be used in everyday clinical practice? The multidisciplinary expert opinion. Chor. Serca Naczyń 2016, 13, 147–158. [Google Scholar]
- Cox, D.; Maree, A.O.; Dooley, M.; Conroy, R.; Byrne, M.F.; Fitzgerald, D.J. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37, 2153–2158. [Google Scholar] [CrossRef] [Green Version]
- Pedersen, A.K.; FitzGerald, G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 1984, 311, 1206–1211. [Google Scholar] [CrossRef]
- Roncucci, L.; Stamp, D.; Medline, A.; Cullen, J.B.; Bruce, W.R. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum. Pathol. 1991, 22, 287–294. [Google Scholar] [CrossRef]
- Percario, R.; Panaccio, P.; di Mola, F.F.; Grottola, T.; Di Sebastiano, P. The Complex Network between Inflammation and Colorectal Cancer: A Systematic Review of the Literature. Cancers 2021, 13, 6237. [Google Scholar] [CrossRef]
- Gustafson-Svard, C.; Lilja, I.; Hallbook, O.; Sjodahl, R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996, 38, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803–809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, P.; Wu, H.; Zhang, H.; Shi, Y.; Xu, J.; Ye, Y.; Xia, D.; Yang, J.; Cai, J.; Wu, Y. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis. Gut 2015, 64, 1419–1425. [Google Scholar] [CrossRef] [PubMed]
- Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302, 649–658. [Google Scholar] [CrossRef]
- Shiff, S.J.; Rigas, B. The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids). J. Exp. Med. 1999, 190, 445–450. [Google Scholar] [CrossRef] [Green Version]
- Long, Q.; Ao, L.; Li, K.; Li, Y. The efficacy and safety of sulindac for colorectal polyps. Medicine 2020, 99, e22402. [Google Scholar] [CrossRef]
- Piazza, G.A.; Rahm, A.L.; Krutzsch, M.; Sperl, G.; Paranka, N.S.; Gross, P.H.; Brendel, K.; Burt, R.W.; Alberts, D.S.; Pamukcu, R. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995, 55, 3110–3116. [Google Scholar]
- Goldberg, Y.; Nassif, I.I.; Pittas, A.; Tsai, L.L.; Dynlacht, B.D.; Rigas, B.; Shiff, S.J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996, 12, 893–901. [Google Scholar]
- Qiao, L.; Shiff, S.J.; Rigas, B. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 1997, 115, 229–234. [Google Scholar] [CrossRef]
- Schmidt, M.; Lamberts, M.; Olsen, A.M.S.; Fosbøll, E.; Niessner, A.; Tamargo, J.; Rosano, G.; Agewall, S.; Kaski, J.C.; Kjeldsen, K.; et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur. Heart J. 2016, 37, 1015–1023. [Google Scholar] [CrossRef] [Green Version]
- Takayama, T.; Nagashima, H.; Maeda, M.; Nojiri, S.; Hirayama, M.; Nakano, Y.; Takahashi, Y.; Sato, Y.; Sekikawa, H.; Mori, M.; et al. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin. Cancer Res. 2011, 17, 3803–3811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cook, N.R.; Lee, I.M.; Gaziano, J.M.; Gordon, D.; Ridker, P.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. Low-Dose Aspirin in the Primary Prevention of Cancer. JAMA 2005, 294, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schoen, R.E.; Mutch, M.; Rall, C.; Dry, S.M.; Seligson, D.; Umar, A.; Pinsky, P. The natural history of aberrant crypt foci. Gastrointest. Endosc. 2008, 67, 1097–1102. [Google Scholar] [CrossRef] [PubMed]
- Stevens, R.G.; Swede, H.; Rosenberg, D.W. Epidemiology of colonic aberrant crypt foci: Review and analysis of existing studies. Cancer Lett. 2007, 252, 171–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baron, J.A.; Cole, B.F.; Sandler, R.S.; Haile, R.W.; Ahnen, D.; Bresalier, R.; McKeown-Eyssen, G.; Summers, R.W.; Rothstein, R.; Burke, C.A.; et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. N. Engl. J. Med. 2003, 348, 891–899. [Google Scholar] [CrossRef]
- Sandler, R.S.; Halabi, S.; Baron, J.A.; Budinger, S.; Paskett, E.; Keresztes, R.; Petrelli, N.; Pipas, J.M.; Karp, D.D.; Loprinzi, C.L.; et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer. N. Engl. J. Med. 2003, 348, 883–890. [Google Scholar] [CrossRef]
- Chan, A.T.; Giovannucci, E.L.; Schernhammer, E.S.; Colditz, G.A.; Hunter, D.J.; Willett, W.C.; Fuchs, C.S. A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma. Ann. Intern. Med. 2004, 140, 157. [Google Scholar] [CrossRef]
- García Rodríguez, L.A.; Huerta-Alvarez, C. Reduced Incidence of Colorectal Adenoma among Long-Term Users of Nonsteroidal Antiinflammatory Drugs: A Pooled Analysis of Published Studies and a New Population-Based Study. Epidemiology 2000, 11, 376–381. [Google Scholar] [CrossRef]
- Tangrea, J.A.; Albert, P.S.; Lanza, E.; Woodson, K.; Corle, D.; Hasson, M.; Burt, R.; Caan, B.; Paskett, E.; Iber, F.; et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003, 14, 403–411. [Google Scholar] [CrossRef]
- Steinbach, G.; Lynch, P.M.; Phillips, R.K.S.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. N. Engl. J. Med. 2000, 342, 1946–1952. [Google Scholar] [CrossRef]
- Ruffin, M.T.; Normolle, D.; Vaerten, M.A.; Normolle, D.; Vaerten, M.A.; Peters-Golden, M.; Crowell, J.; Kelloff, G.; Boland, C.R.; Brenner, D.E. Suppression of Human Colorectal Mucosal Prostaglandins: Determining the Lowest Effective Aspirin Dose. JNCI 1997, 89, 1152–1160. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chan, A.T.; Meyerhardt, J.A.; Giovannucci, E.L. Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study. J. Natl. Cancer Inst. 2021, 113, 841–851. [Google Scholar] [CrossRef] [PubMed]
- Patrono, C.; Coller, B.; Dalen, J.E.; FitzGerald, G.A.; Fuster, V.; Gent, M.; Hirsh, J.; Roth, G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001, 119, 39S–63S. [Google Scholar] [CrossRef] [PubMed]
- Chan, T.A.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95, 681–686. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells. Cell 1998, 93, 705–716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kardasz, M.; Pawłowska, D. The role of dietary components and different substance in the development of cancer. Nowa Med. 2008, 2, 7–14. [Google Scholar]
- Grau, M.V.; Sandler, R.S.; McKeown-Eyssen, G.; Bresalier, R.S.; Haile, R.W.; Barry, E.L.; Ahnen, D.J.; Gui, J.; Summers, R.W.; Baron, J.A. Nonsteroidal Anti-inflammatory Drug Use After 3 Years of Aspirin Use and Colorectal Adenoma Risk: Observational Follow-up of a Randomized Study. J. Natl. Cancer Inst. 2009, 101, 267–276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gann, P.H.; Manson, J.E.; Glynn, R.J.; Buring, J.E.; Hennekens, C.H. Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized Trial. J. Natl. Cancer Inst. 1993, 85, 1220–1224. [Google Scholar] [CrossRef]
- Dulai, P.S.; Singh, S.; Marquez, E.; Khera, R.; Prokop, L.J.; Limburg, P.J.; Gupta, S.; Murad, M.H. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis. BMJ 2016, 355, i6188. [Google Scholar] [CrossRef] [Green Version]
- Moxon, D.; Raza, M.; Kenney, R.; Ewing, R.; Arozullah, A.; Mason, J.B.; Carroll, R.E. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin. Gastroenterol. Hepatol. 2005, 3, 271–278. [Google Scholar] [CrossRef]
- Rudolph, R.E.; Dominitz, J.A.; Lampe, J.W.; Levy, L.; Qu, P.; Li, S.S.; Lampe, P.D.; Bronner, M.P.; Potter, J.D. Risk Factors for Colorectal Cancer in Relation to Number and Size of Aberrant Crypt Foci in Humans. Cancer Epidemiol. Biomark. Prev. 2005, 14, 605–608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kowalczyk, M.; Orłowski, M.; Siermontowski, P.; Mucha, D.; Zinkiewicz, K.; Kurpiewski, W.; Zieliński, E.; Kowalczyk, I.; Pedrycz, A. Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients. BMC Cancer 2018, 18, 213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kowalczyk, M.; Siermontowski, P.; Mucha, D.; Ambroży, T.; Orłowski, M.; Zinkiewicz, K.; Kurpiewski, W.; Paśnik, K.; Kowalczyk, I.; Pedrycz, A. Chromoendoscopy with a Standard-Resolution Colonoscope for Evaluation of Rectal Aberrant Crypt Foci. PLoS ONE 2016, 11, e0148286. [Google Scholar] [CrossRef] [PubMed]
- Kowalczyk, M.; Klepacki, Ł.; Zieliński, E.; Kurpiewski, W.; Zinkiewicz, K.; Dyśko, Ł.; Pesta, W. The Effect of Smoking on the Number and Type of Rectal Aberrant Crypt Foci (ACF)—First Identifiable Precursors of Colorectal Cancer (CRC). J. Clin. Med. 2021, 10, 55. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Schut, H.A.J.; Conran, P.; Kramer, P.M.; Lubet, R.A.; Steele, V.E.; Hawk, E.E.; Kelloff, G.J.; Pereira, M.A. Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999, 20, 425–430. [Google Scholar] [CrossRef] [PubMed]
- Higurashi, T.; Arimoto, J.; Ashikari, K.; Takatsu, T.; Misawa, N.; Yoshihara, T.; Matsuura, T.; Fuyuki, A.; Ohkubo, H.; Nakajima, A. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: A double-blinded randomized controlled trial. BMC Cancer 2020, 20, 1043. [Google Scholar] [CrossRef]
- Hosono, K.; Endo, H.; Takahashi, H.; Sugiyama, M.; Sakai, E.; Uchiyama, T.; Suzuki, K.; Iida, H.; Sakamoto, Y.; Yoneda, K.; et al. Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial. Cancer Prev. Res. 2010, 3, 1077–1083. [Google Scholar] [CrossRef] [Green Version]
- Higurashi, T.; Hosono, K.; Takahashi, H.; Komiya, Y.; Umezawa, S.; Sakai, E.; Uchiyama, T.; Taniguchi, L.; Hata, Y.; Uchiyama, S.; et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016, 17, 475–483. [Google Scholar] [CrossRef]
Age Group | Type of Aberrant Crypt Foci | |||||||
---|---|---|---|---|---|---|---|---|
Normal | Hyperplastic | Dysplastic | Mixed | |||||
With ASA | Without ASA | With ASA | Without ASA | With ASA | Without ASA | With ASA | Without ASA | |
1. <50 | 0 | 18 | 0 | 11 | 0 | 1 | 0 | 0 |
2. 50–60 | 2 | 25 | 3 | 10 | 1 | 2 | 0 | 4 |
3. 60–70 | 0 | 11 | 3 | 8 | 1 | 4 | 0 | 4 |
4. >70 | 7 | 10 | 5 | 9 | 2 | 5 | 0 | 3 |
Total | 9 | 64 | 11 | 38 | 4 | 12 | 0 | 11 |
Age Group | Adenoma | Hyperplastic Polyp | Serated Polyp | |||
---|---|---|---|---|---|---|
With ASA | Without ASA | With ASA | Without ASA | With ASA | Without ASA | |
1. <50 | 0 | 4 | 0 | 8 | 0 | 1 |
2. 50–60 | 0 | 10 | 6 | 12 | 1 | 3 |
3. 60–70 | 0 | 14 | 2 | 16 | 1 | 4 |
4. >70 | 2 | 18 | 6 | 12 | 1 | 2 |
Total | 2 | 46 | 14 | 48 | 3 | 10 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kowalczyk, M.; Sigorski, D.; Dyśko, Ł.; Zieliński, E.; Zupanovich Lucka, D.; Klepacki, Ł. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci. Medicina 2022, 58, 1767. https://doi.org/10.3390/medicina58121767
Kowalczyk M, Sigorski D, Dyśko Ł, Zieliński E, Zupanovich Lucka D, Klepacki Ł. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci. Medicina. 2022; 58(12):1767. https://doi.org/10.3390/medicina58121767
Chicago/Turabian StyleKowalczyk, Marek, Dawid Sigorski, Łukasz Dyśko, Ewa Zieliński, Dana Zupanovich Lucka, and Łukasz Klepacki. 2022. "The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci" Medicina 58, no. 12: 1767. https://doi.org/10.3390/medicina58121767